Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Carotuximab - Enviro Therapeutics

Next Previous
Drug Profile

Carotuximab - Enviro Therapeutics

Alternative Names: Chimeric Antibody TRC105; DE-122; ENV-105; NSC#754227; TRC-105

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Roswell Park Cancer Institute
  • Developer Enviro Therapeutics; National Cancer Institute (USA); Santen Pharmaceutical; TRACON Pharmaceuticals; University of Alabama at Birmingham; University of Minnesota
  • Class Antifibrotics; Antineoplastics; Eye disorder therapies; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Angiogenesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Soft tissue sarcoma
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Prostate cancer
  • Phase I Non-small cell lung cancer
  • Discontinued Acute myeloid leukaemia; Breast cancer; Choriocarcinoma; Colorectal cancer; Fallopian tube cancer; Glioblastoma; Haemangiosarcoma; Liver cancer; Ovarian cancer; Peritoneal cancer; Precursor B-cell lymphoblastic leukaemia-lymphoma; Renal cell carcinoma; Soft tissue sarcoma; Wet age-related macular degeneration

Most Recent Events

  • 15 Sep 2023 Phase-I clinical trials in Non-small cell lung cancer (Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (IV) (NCT05401110)
  • 15 Oct 2020 Tracon Pharmaceuticals terminates the phase II TRAXAR trial in Renal cell carcinoma (Combination therapy, Late-stage disease, Second-line therapy or greater) in Czech Republic, Hungary, Poland, United Kingdom and USA (IV) (NCT01806064) (EudraCT2015-003436-13)
  • 09 Mar 2020 Discontinued - Phase-I/II for Wet age-related macular degeneration in USA (Intravitreous)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top